Maria G. Narducci

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

CXCL13 as a simple and promising blood biomarker for differentiating Sézary syndrome from mycosis fungoides and other confounding chronic inflammatory skin diseases.

CXCL13 as a simple and promising blood biomarker for differentiating Sézary syndrome from mycosis fungoides and other confounding chronic inflammatory skin diseases.

Journal: Frontiers in immunology

Published: February 04, 2026

Expressed mutated genes in Sezary syndrome and their potential prognostic value in patients treated with extracorporeal photopheresis.

Expressed mutated genes in Sezary syndrome and their potential prognostic value in patients treated with extracorporeal photopheresis.

Journal: Frontiers in immunology

Published: March 07, 2025

Role of Neutrophil-to-Lymphocyte Ratio (NLR) in Patients with Mycosis Fungoides.

Role of Neutrophil-to-Lymphocyte Ratio (NLR) in Patients with Mycosis Fungoides.

Journal: Diagnostics (Basel, Switzerland)

Published: May 05, 2023

Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy.

Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy.

Journal: Cancers

Published: May 26, 2022

Combined High-Throughput Approaches Reveal the Signals Driven by Skin and Blood Environments and Define the Tumor Heterogeneity in Sézary Syndrome.

Combined High-Throughput Approaches Reveal the Signals Driven by Skin and Blood Environments and Define the Tumor Heterogeneity in Sézary Syndrome.

Journal: Cancers

Published: May 03, 2022

Genetically Driven CD39 Expression Affects Sezary Cell Viability and IL-2 Production and Detects Two Patient Subsets with Distinct Prognosis.

Genetically Driven CD39 Expression Affects Sezary Cell Viability and IL-2 Production and Detects Two Patient Subsets with Distinct Prognosis.

Journal: The Journal of investigative dermatology

Published: August 01, 2021

Challenging Cutaneous T-Cell Lymphoma: What Animal Models Tell us So Far.

Challenging Cutaneous T-Cell Lymphoma: What Animal Models Tell us So Far.

Journal: The Journal of investigative dermatology

Published: July 29, 2021

Continuous low-dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective study.

Continuous low-dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective study.

Journal: Dermatologic therapy

Published: June 13, 2021

Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.

Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.

Journal: Frontiers in immunology

Published: July 03, 2020

Protein kinase Akt2/PKBβ is involved in blastomere proliferation of preimplantation mouse embryos.

Protein kinase Akt2/PKBβ is involved in blastomere proliferation of preimplantation mouse embryos.

Journal: Journal of cellular physiology

Published: May 24, 2019

Loss of β-arrestin-2 gene and possible functional consequences on Sezary Syndrome.

Loss of β-arrestin-2 gene and possible functional consequences on Sezary Syndrome.

Journal: Cell cycle (Georgetown, Tex.)

Published: May 21, 2019

Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma.

Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma.

Journal: The Journal of investigative dermatology

Published: May 20, 2019

Showing 1-12 of 23

Last Updated: 09/26/2026